Literature DB >> 8917195

Consensus on diuresis renography for investigating the dilated upper urinary tract. Radionuclides in Nephrourology Group. Consensus Committee on Diuresis Renography.

P O'Reilly1, M Aurell, K Britton, K Kletter, L Rosenthal, T Testa.   

Abstract

UNLABELLED: There is great variation in technique and interpretation of diuresis renography between different establishments.
METHODS: To address this problem, an International Consensus Committee was appointed by the Ninth International Symposium on Radionuclides in Nephrourology in 1994.
RESULTS: The final document was produced and addressed: objectives, equipment, data acquisition, choice of radiopharmaceutical, patient preparation, position, dosage of furosemide, timing of furosemide, role of bladder catheter, duration of study, pediatric considerations, evaluation of the furosemide response, interpretation, and conclusion.
CONCLUSION: The report presents a standardized approach to diuresis renography that, if adopted, will improve reproducibility between centers, discourage unacceptable practice and stimulate further discussion between nuclear medicine and urology health care professionals who treat patients with dilated and obstructed upper urinary tracts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8917195

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  34 in total

Review 1.  Fetal genitourinary imaging.

Authors:  Teresa Chapman
Journal:  Pediatr Radiol       Date:  2012-03-06

2.  iRENEX: a clinically informed decision support system for the interpretation of ⁹⁹mTc-MAG3 scans to detect renal obstruction.

Authors:  Ernest V Garcia; Andrew Taylor; Russell Folks; Daya Manatunga; Raghuveer Halkar; Bital Savir-Baruch; Eva Dubovsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-30       Impact factor: 9.236

3.  [Functional and morphological MR imaging of the upper urinary tract in the pediatric age group].

Authors:  W K Rohrschneider; J-P Schenk
Journal:  Radiologe       Date:  2005-12       Impact factor: 0.635

4.  Evaluation of two diuresis renography decision support systems to determine the need for furosemide in patients with suspected obstruction.

Authors:  Andrew Taylor; Andrew N Hill; José N E Binongo; Amita K Manatunga; Raghuveer Halkar; Eva V Dubovsky; Ernest V Garcia
Journal:  AJR Am J Roentgenol       Date:  2007-05       Impact factor: 3.959

5.  SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0.

Authors:  Andrew T Taylor; David C Brandon; Diego de Palma; M Donald Blaufox; Emmanuel Durand; Belkis Erbas; Sandra F Grant; Andrew J W Hilson; Anni Morsing
Journal:  Semin Nucl Med       Date:  2018-03-16       Impact factor: 4.446

6.  The SNMMI and EANM practice guideline for renal scintigraphy in adults.

Authors:  M Donald Blaufox; Diego De Palma; Andrew Taylor; Zsolt Szabo; Alain Prigent; Martin Samal; Yi Li; Andrea Santos; Giorgio Testanera; Mark Tulchinsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-30       Impact factor: 9.236

7.  Re(CO)3([18F]FEDA), a novel 18F PET renal tracer: Radiosynthesis and preclinical evaluation.

Authors:  Malgorzata Lipowska; Nashwa Jarkas; Ronald J Voll; Jonathon A Nye; Jeffrey Klenc; Mark M Goodman; Andrew T Taylor
Journal:  Nucl Med Biol       Date:  2017-12-27       Impact factor: 2.408

8.  99mTc-MAG3: Image Wisely.

Authors:  Andrew T Taylor; Russell D Folks; A K M Fazlur Rahman; Aruna Polsani; Eva V Dubovsky; Raghuveer Halkar; Amita Manatunga
Journal:  Radiology       Date:  2017-02-17       Impact factor: 11.105

9.  99mTc(CO)3(NTA) and 131I-OIH: comparable plasma clearances in patients with chronic kidney disease.

Authors:  Andrew T Taylor; Malgorzata Lipowska; Hui Cai
Journal:  J Nucl Med       Date:  2013-02-19       Impact factor: 10.057

Review 10.  Radionuclides in nephrourology, part 1: Radiopharmaceuticals, quality control, and quantitative indices.

Authors:  Andrew T Taylor
Journal:  J Nucl Med       Date:  2014-02-18       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.